The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Open accessAbstract
Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving tumours. Although vaccine approaches have had some clinical success, most cancer vaccines fail to induce objective tumour shrinkage in patients. More-recent approaches have centred on a series of molecules known as immune checkpoints—whose natural function is to restrain or dampen a potentially over-exuberant response. Blocking immune checkpoint molecules with monoclonal antibodies has emerged as a viable clinical strategy that mediates tumour shrinkage in several cancer types. In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retracted: Immunotherapy of metastatic renal cell carcinoma
McDermott, D. F. (2009) · Cancer · doi:10.1002/cncr.24236 · Cited by 118
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Self-citationTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Self-citationCancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T., & Old, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1669 · Cited by 1,582
Innate immune recognition: mechanisms and pathways
Medzhitov, R., & Janeway, C. J. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.917309.x · Cited by 1,506
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Self-citationCo-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M., Konto, C., & Wolchok, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 714
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Self-citationNorth, R. J. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.1063 · Cited by 650
T-cell-antigen recognition and the immunological synapse
Huppa, J. B., & Davis, M. M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1245 · Cited by 643
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
The integration of T cell migration, differentiation and function
Masopust, D., & Schenkel, J. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3442 · Cited by 627
Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
Self-citationDurable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Self-citationKaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 453
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Ulloa-Montoya, F., Louahed, J., Dizier, B., Gruselle, O., Spiessens, B., Lehmann, F. F., Suciu, S., Kruit, W. H. J., Eggermont, A. M. M., Vansteenkiste, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3762 · Cited by 436
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulières, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 428
Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. J., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199802001-00032 · Cited by 410
Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 367
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Quoix, E., Ramlau, R., Westeel, V., Papai, Z., Madroszyk, A., Riviere, A., Koralewski, P., Breton, J.-L., Stoelben, E., Braun, D., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70259-5 · Cited by 269
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V., Chin, K., Canetta, R., & Humphrey, R. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.015 · Cited by 242
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
Ramlau, R., Quoix, E., Rolski, J., Pless, M., Lena, H., Lévy, E., Krzakowski, M., Hess, D., Tartour, E., Chenard, M.-P., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b4f · Cited by 209
Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results
Cluff, C. W. (2009) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-1603-7_10 · Cited by 205
Herbst, R. S., Gordon, M. S., Fine, G. D., Sosman, J. A., Soria, J.-C., Hamid, O., Powderly, J. D., Burris, H. A., Mokatrin, A., Kowanetz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3000 · Cited by 190
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Goldberg, M. V., Maris, C. H., Hipkiss, E. L., Flies, A. S., Zhen, L., Tuder, R. M., Grosso, J. F., Harris, T. J., Getnet, D., Whartenby, K. A., et al. (2007) · Blood · doi:10.1182/blood-2006-12-062422 · Cited by 187
Self-citationL-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
Sangha, R., & Butts, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0213 · Cited by 173
Rochlitz, C., Figlin, R., Squiban, P., Salzberg, M., Pless, M., Herrmann, R., Tartour, E., Zhao, Y., Bizouarne, N., Baudin, M., et al. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.397 · Cited by 172
Spontaneous regression of cancer
Papac, R. J. (1996) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(96)90023-7 · Cited by 168
Brichard, V. G., & Lejeune, D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.038 · Cited by 160
Kruit, W. H. J., van Ojik, H. H., Brichard, V. G., Escudier, B. J., Dorval, T., Dréno, B., Patel, P. M., van Baren, N., Avril, M., Piperno‐Neumann, S., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21264 · Cited by 160
Hsueh, E. C., Gupta, R. K., Qi, K., & Morton, D. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2913 · Cited by 158
Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H., Goldberg, M. V., Grosso, J. F., Getnet, D., Marzo, A. M. D., Netto, G. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4102 · Cited by 158
Self-citationGrosso, J., Horak, C. E., Inzunza, D., Cardona, D. M., Simon, J. S., Gupta, A. K., Sankar, V., Park, J.-S., Kollia, G., Taube, J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3016 · Cited by 158
Vansteenkiste, J., Zielinski, M., Linder, A., Dahabre, J., Esteban, E., Malinowski, W., Jassem, J., Passlick, B., Lehmann, F. F., & Brichard, V. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7554 · Cited by 151
Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147
Melanoma as a model tumour for immuno-oncology
Maio, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds257 · Cited by 127
Andtbacka, R. H. I., Collichio, F. A., AMATRUDA, T. T., Senzer, N. N., Chesney, J. A., Delman, K. A., S̄pitler, L. E., Puzanov, I. J., Doleman, S., Ye, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.lba9008 · Cited by 119
GM-CSF Gene-Transduced Tumor Vaccines
Eager, R. M., & Nemunaitis, J. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.012 · Cited by 108
Luiten, R. M., Taanman-Kueter, E. W., Mooi, W. J., Gallee, M. P. W., Rankin, E. M., Gerritsen, W. R., Clift, S., Nooijen, W. J., Weder, P., van de Kasteele, W., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6816 · Cited by 107
Emerging immunotherapies for renal cell carcinoma
Escudier, B. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds261 · Cited by 104
Oudard, S., Rixe, O., Beuselinck, B., Linassier, C., Banu, E., Machiels, J., Baudard, M., Ringeisen, F., Velu, T., Lefrère-Belda, M., et al. (2011) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-010-0935-9 · Cited by 101
Cho, D. C., Sosman, J. A., Sznol, M., Gordon, M. S., Hollebecque, A., Hamid, O., McDermott, D. F., Delord, J., Rhee, I. P., Mokatrin, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4505 · Cited by 97
Brahmer, J. R., Horn, L., Antonia, S. J., Spigel, D. R., Gandhi, L., Sequist, L. V. D., Sankar, V., Ahlers, C. M., Wigginton, J. M., Kollia, G. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8030 · Cited by 74
Self-citationTopalian, S. L., Sznol, M., Brahmer, J. R., McDermott, D. F., Smith, D. C., Gettinger, S. N., Taube, J. M., Drake, C. G., Pardoll, D. M., Powderly, J. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3002 · Cited by 72
Self-citationImmunotherapy Via Dendritic Cells
Palucka, A. K., Laupèze, B., Aspord, C., Saito, H., Jégo, G., Fay, J. W., Paczesny, S., Pascual, V., & Banchereau, J. (2005) · Advances in experimental medicine and biology · doi:10.1007/0-387-24180-9_14 · Cited by 60
Butts, C. A., Socinski, M. A., Mitchell, P. L. R., Thatcher, N., Havel, L., Krzakowski, M. J., Nawrocki, S., Ciuleanu, T., Bosquée, L., Perez, J. M. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.7500 · Cited by 60
Vansteenkiste, J., Zielinski, M., Dahabreh, I. J., Linder, A., Lehmann, F., Gruselle, O., Therasse, P., Louahed, J., & Brichard, V. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.7501 · Cited by 58
Sznol, M., Kluger, H. M., Hodi, F. S., McDermott, D. F., Carvajal, R. D., Lawrence, D. P., Topalian, S. L., Atkins, M. B., Powderly, J. D., Sharfman, W. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.cra9006 · Cited by 58
Drake, C. G., McDermott, D. F., Sznol, M., Choueiri, T. K., Kluger, H. M., Powderly, J. D., Smith, D. C., Sankar, V., Gutierrez, A. A., Wigginton, J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4514 · Cited by 55
Self-citationImmunotherapeutic strategies in kidney cancer—when TKIs are not enough
Biswas, S., & Eisen, T. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.91 · Cited by 49
The development of immunotherapies for non-small cell lung cancer
Salgaller, M. L. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.3.265 · Cited by 49
Hodi, F. S., Lee, S. J., McDermott, D. F., Rao, U. N. M., Butterfield, L. H., Tarhini, A. A., Leming, P. D., Puzanov, I. J., Kirkwood, J. M., & Eastern Cooperative Oncology Group (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.cra9007 · Cited by 46
Sznol, M., Kluger, H. M., Hodi, F. S., McDermott, D. F., Carvajal, R. D., Lawrence, D. P., Topalian, S. L., Atkins, M. B., Powderly, J. D., Sharfman, W. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.cra9006 · Cited by 43
Arlen, P. M., Kaufman, H. L., & DiPaola, R. S. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.006 · Cited by 40
Hodi, F. S., Lee, S. J., McDermott, D. F., Rao, U. N. M., Butterfield, L. H., Tarhini, A. A., Leming, P. D., Puzanov, I. J., Kirkwood, J. M., & Eastern Cooperative Oncology Group (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.cra9007 · Cited by 31
Figlin, R. A., Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Master, V. A., Pal, S. K., Gamble, A. H., Debenedette, M. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.5_suppl.348 · Cited by 22
Cited by
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J. C., Rodig, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,451
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 754
Autophagy, Metabolism, and Cancer
White, E., Mehnert, J. M., & Chan, C. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0490 · Cited by 664
Sharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
Self-citation
Metadata
- Authors
- Drake, C. G., Lipson, E. J., & Brahmer, J. R.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-11-19
- Volume
- 11
- Issue
- 1
- Pages
- 24-37
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2135885240
- Cited by
- 422
- References
- 86
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.